India NewsNews

Expert Panel Meeting on Serum’s Application for emergency use of Covishield

A meeting will be held today to consider the application of Serum Institute of India for the emergency use of the Covid-19 vaccine on behalf of the Subject Expert Committee of the Drugs Controller of India.

To prevent Coronavirus, the vaccine of Coronavirus has been approved in many countries. At the same time, in India, the coronavirus vaccine is waiting to be approved. It is believed that soon the Coronavirus vaccine will be approved in India too. Meanwhile, the Subject Expert Committee (SEC) will meet today to consider the application of the Serum Institute of India.

The Serum Institute of India recently applied to the government for emergency use of the Coronavirus vaccine made by Oxford University. Now a government official quoting the news agency ANI said that today a meeting of the Subject Expert Committee (SEC) of Drugs Controller of India to consider the application of Serum Institute of India for emergency use of Covid-19 vaccine Will.

Serum Institute of India, the world’s largest vaccine manufacturer, has already applied for the emergency use of the Covishield vaccine. The Serum Institute of India has named the Oxford AstraZeneca Covid-19 vaccine as Covishield. Millions of doses of this vaccine have already been prepared by Serum.

The Serum Institute of India has so far produced around five crore doses of the Oxford AstraZeneca Covid-19 vaccine. The Serum Institute says that its target is to produce 100 million doses by March of the year 2021. The company’s CEO Adar Poonawala said that we are awaiting approval for emergency use of this vaccine.

Back to top button